Impact of therapy on the outcome of chronic hepatitis B.
about
Natural regression of fibrosis in chronic hepatitis BKASL clinical practice guidelines: management of chronic hepatitis BAntiviral therapy for chronic hepatitis B in ChinaPrevention of hepatocellular carcinoma in patients with chronic hepatitis BRole of antiviral therapy in the natural history of hepatitis B virus-related chronic liver diseaseDNA Polymerase κ Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B VirusNovel natural mutations in the hepatitis B virus reverse transcriptase domain associated with hepatocellular carcinoma.Large dosage of chishao in formulae for cholestatic hepatitis: a systematic review and meta-analysis.Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: a head-to-head study.Chronic hepatitis B and liver cancer risks among Asian immigrants in New York City: Results from a large, community-based screening, evaluation, and treatment program.The hepatitis B virus ribonuclease H as a drug targetSequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil.Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice.The frequency and skewed T-cell receptor beta-chain variable patterns of peripheral CD4(+)CD25(+) regulatory T-cells are associated with hepatitis B e antigen seroconversion of chronic hepatitis B patients during antiviral treatment.Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it?PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cureMetabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.In Vitro Enzymatic and Cell Culture-Based Assays for Measuring Activity of HBV RNaseH Inhibitors.Characterization of novel hepadnaviral RNA species accumulated in hepatoma cells treated with viral DNA polymerase inhibitorsAssessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg.Efficacy of entecavir therapy for hepatitis B e-antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues.Correlation between HBsAg quantitation and HBV DNA in HBeAg-negative HBV/D patients.Comparison of repeated surgical resection and radiofrequency ablation for small recurrent hepatocellular carcinoma after primary resection.Baseline and serial liver stiffness measurement in prediction of portal hypertension progression for patients with compensated cirrhosis.
P2860
Q26746929-3733FAD7-F821-4691-A733-E4460FC8B8DEQ26752475-7361E5C3-D478-4F34-A085-48C14CD6580EQ27006557-96506C5E-F52D-46B8-9E04-8887A69540A4Q27023997-6EC87E10-1BF1-486B-98DC-EC35C7B68359Q28088566-C55406BD-6518-4006-BBBA-AB0ABB34EDDDQ28552967-4D746D0E-9070-4F1E-8459-B1A29FA83103Q33553814-69532D00-A46E-4E62-A655-2A9659A910A9Q33766461-6D44FFA5-5801-4D9E-9328-97E8366D42EDQ34735876-AA9B9817-6C82-4953-B300-B92E5B6A28EAQ35215610-E95C9F73-CEC4-4725-94B2-01EC3B69B012Q35582561-8B40EE40-49E4-4597-BB77-E0EAC72FFD54Q35746110-61C4D60B-D61E-4A2D-BCE8-33247AFC9E62Q36793870-2BA037A3-2C7B-4EF1-8F77-07C47FC2C8DFQ36922392-F50B4797-5574-4152-94DF-1C501047B635Q37284974-698B57A5-EBE4-4E7C-9AEC-06F1621EEC64Q37408912-D2E1C2C9-04E8-4640-B627-7FDB5A50749DQ38102776-B50AD395-EB25-4A8E-B1B9-1A6DC09F6F19Q38553065-D4CCC162-B96D-4E61-B93B-352450BA635EQ38566445-1313AF4E-8B40-4D9A-ACFB-329C0170222BQ40409344-0B7E6DC4-F100-4FF3-B801-0FE14FC04ED4Q40798098-2FD3F947-EA69-42C7-AB5A-9693EA2ABCEFQ40817492-F17E29DC-1347-4155-9F5F-94EEFCAFEE77Q41284684-DDC0AB2F-1FC2-4535-87E1-08C801F1FAB8Q42407103-A912E37C-0C26-4DE7-8CAD-9D0503AEE126Q47158857-7EDA49A0-D3A0-42E4-94DA-4CDAFBFC8589Q51102598-79610D82-764B-4FD3-9AD4-4FEE4532E8A3
P2860
Impact of therapy on the outcome of chronic hepatitis B.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Impact of therapy on the outcome of chronic hepatitis B.
@en
type
label
Impact of therapy on the outcome of chronic hepatitis B.
@en
prefLabel
Impact of therapy on the outcome of chronic hepatitis B.
@en
P2860
P356
P1433
P1476
Impact of therapy on the outcome of chronic hepatitis B.
@en
P2860
P304
P356
10.1111/LIV.12057
P478
33 Suppl 1
P50
P577
2013-02-01T00:00:00Z